ARTICLE | Clinical News

Acorda falls on tozadenant safety concerns

November 15, 2017 11:03 PM UTC

Acorda Therapeutics Inc. (NASDAQ:ACOR) lost $11.20 (40%) to $17 on Wednesday after disclosing cases of agranulocytosis that were possibly related to treatment with Parkinson's disease candidate tozadenant (SYN115) and in some cases associated with sepsis and death.

Among about 890 patients who received the selective adenosine A2A receptor (ADORA2A) antagonist across the company's Phase IIb and Phase III trials, Acorda reported seven cases of sepsis in the tozadenant arms, five of which were fatal. Furthermore, four of the sepsis cases were associated with agranulocytosis, including two patients with no white blood cell counts at the time of the event...

BCIQ Company Profiles

Acorda Therapeutics Inc.